Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension
about
DNA Damage and Pulmonary HypertensionPotent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY-8040 in a Pulmonary Arterial Hypertension Rat ModelEvaluating the Stability of RNA-Seq Transcriptome Profiles and Drug-Induced Immune-Related Expression Changes in Whole BloodThe protective effects of PCPA against monocrotaline-induced pulmonary arterial hypertension are mediated through the downregulation of NFAT-1 and NF-κBThe cancer theory of pulmonary arterial hypertension.Hypoxia-Inducible Factor 1α Is a Critical Downstream Mediator for Hypoxia-Induced Mitogenic Factor (FIZZ1/RELMα)-Induced Pulmonary Hypertension.Role of prostacyclin in pulmonary hypertension.Endothelial CD74 mediates macrophage migration inhibitory factor protection in hyperoxic lung injuryHigh-mobility group box-1 induces vascular remodelling processes via c-Jun activationProgress in the understanding and management of pulmonary arterial hypertension.The Effects of Antigen-Specific IgG1 Antibody for the Pulmonary-Hypertension-Phenotype and B Cells for Inflammation in Mice Exposed to Antigen and Fine Particles from Air Pollution.Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.Metabolic Changes Precede the Development of Pulmonary Hypertension in the Monocrotaline Exposed Rat Lung.Transcriptome Analysis and Gene Identification in the Pulmonary Artery of Broilers with Ascites Syndrome.Update in Pulmonary Vascular Diseases 2014.Acute effects of exercise on the inflammatory state in patients with idiopathic pulmonary arterial hypertension.Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variabilityThe HLA-B*35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients.Nitro-fatty acids in cardiovascular regulation and diseases: characteristics and molecular mechanisms.Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice.Inhibitory effect of Bailing capsule on hypoxia-induced proliferation of rat pulmonary arterial smooth muscle cellsProlyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2α.Pulmonary arterial hypertension secondary to adult-onset Still's disease: Response to cyclosporine and sildenafil over 15 years of follow-up.Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model.Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.Activation of the nicotinamide N-methyltransferase (NNMT)-1-methylnicotinamide (MNA) pathway in pulmonary hypertension.Versican accumulates in vascular lesions in pulmonary arterial hypertension.Benefits from the correction of vitamin D deficiency in patients with pulmonary hypertension.Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathwaysLow-density lipoprotein cholesterol and survival in pulmonary arterial hypertension.Differential expression of microRNA in the lungs of rats with pulmonary arterial hypertension.Novel Targets of Drug Treatment for Pulmonary Hypertension.Origin and production of inflammatory perivascular macrophages in pulmonary hypertension.Molecular pathogenesis and current pathology of pulmonary hypertension.Importance of kynurenine in pulmonary hypertension.BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease.Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations.Pulmonary hypertension in the premature infant: a challenging comorbidity in a vulnerable population.Lung Circulation.
P2860
Q27005594-DD7A629E-CE7A-4167-8E44-DE73C80179FEQ27702090-73BC10EF-3C5A-46D8-B150-2B6BC04A7AD7Q28546581-26C94F7B-4813-4DBB-8C0B-AA2566F111FFQ33783941-C9EA554F-DB99-4937-AE92-E9829C2F0D4FQ33788493-40BC1611-4370-40CA-9E66-16A8902619C4Q33920050-E1259EAE-6009-43F5-A143-5C340F8C4A1CQ35165100-793606B5-CB37-4C72-A161-946735CA4BBCQ35555139-D1C0ED20-11E9-48E3-8F5F-73B2C972695CQ35571972-CD074940-F79B-413F-A823-C0D9E1EB2C0AQ35662646-FB8266F1-0FBB-45AA-A6F1-4ED5C9C02765Q35665034-62C075F0-027E-4D2A-BF26-0817A72F256DQ35766693-EBC92B10-946F-4839-AFC3-D844E28DB5A7Q35944064-4A129B0D-647D-4D91-9F43-917191C72B18Q36044926-9A44939A-07BC-4171-8193-2F1FDED98656Q36128639-2FE6CCDD-A052-4BE8-85FC-9DEA9B6AD4D3Q36190169-4B54708C-DF44-4B4D-B24A-3D719DD39784Q36382353-B551CA3A-D338-43A8-89FE-F62C9E79BA9AQ36439989-C6CEDB7C-BAD7-411F-9E5D-580254F0E28BQ36565424-DFD281EC-EAA2-484B-A06A-65CD07DEB120Q36916730-00228332-90F3-411E-9E53-653EBF570244Q36936599-3DAFF963-1C5C-4CEB-9475-B078FB9BDE93Q37004101-81F731B3-7B93-4D45-8B15-F8AB827F80E1Q37053491-5D6CD0B8-73F0-4403-A4F3-8BEE9C2AE1A3Q37112304-DC113906-4B92-4E5D-9C05-604D6A841CCAQ37217507-1E775A98-4482-4B4A-B2A8-963520A6491DQ37223938-9B982BCF-42B8-43DB-AE01-D61A2EA1C946Q37248333-E62EE66E-A261-4E68-A21D-79C6324041E4Q37497182-A4DB7339-8B9C-4565-AAFF-56ACC1885912Q37620501-C377DC4D-46BD-4E07-9B0C-11054A02D0A6Q37642747-AAB093AE-4D54-41F6-B518-2AB34116822DQ38438856-7E5BD68A-76F7-486F-B2FF-2C1489DE8B69Q38504399-8B4A65B5-604C-4FF4-9BDB-0C5B0972B808Q38601788-5637285F-0F34-45E0-BCC5-4C9D1B429634Q38676413-1AE1CC46-AA5B-4F3A-B849-3805FE939569Q38680121-95A1A750-3481-4E05-84ED-4A19FE306D3EQ38732718-F72A26D7-DD84-4330-8BB1-799A9B0DD7BFQ38736112-051808FF-14B0-4046-84FB-7FFE8B7862D6Q38779774-C9917DA7-0793-4DAD-95B4-EBAAAA9EB30CQ38797632-76505804-FE8E-4092-95E4-EB6517E731C8Q38804579-85A1423A-1B3E-40B8-91AF-22837FDEF409
P2860
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension
@ast
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension
@en
type
label
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension
@ast
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension
@en
prefLabel
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension
@ast
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension
@en
P2093
P2860
P1433
P1476
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension
@en
P2093
Christophe Guignabert
Mark R Nicolls
Marlene Rabinovitch
P2860
P304
P356
10.1161/CIRCRESAHA.113.301141
P50
P577
2014-06-01T00:00:00Z